


## PHARMACEUTICAL 2018

## **OncoMed Pharmaceuticals Inc** Rank 166 of 349





## PHARMACEUTICAL 2018

## OncoMed Pharmaceuticals Inc Rank 166 of 349

The relative strengths and weaknesses of OncoMed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OncoMed Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 107% points. The greatest weakness of OncoMed Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 51% points.

The company's Economic Capital Ratio, given in the ranking table, is -157%, being 120% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	105,205
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	93,132
Liabilities, Non-Current	0
Other Assets	1,842
Other Compr. Net Income	29
Other Expenses	1,444
Other Liabilities	65,793
Other Net Income	828
Property and Equipment	3,275
Research and Development	59,839
Revenues	38,154
Selling, General and Administrative Expense	16,761

Output Variable	Value in 1000 USD
Assets	110,322
Liabilities	158,925
Expenses	78,044
Stockholders Equity	-48,603
Net Income	-39,062
Comprehensive Net Income	-39,048
Economic Capital Ratio	-157%